ES2077345T3 - INTERMEDIARIES OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND USE. - Google Patents

INTERMEDIARIES OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND USE.

Info

Publication number
ES2077345T3
ES2077345T3 ES92202494T ES92202494T ES2077345T3 ES 2077345 T3 ES2077345 T3 ES 2077345T3 ES 92202494 T ES92202494 T ES 92202494T ES 92202494 T ES92202494 T ES 92202494T ES 2077345 T3 ES2077345 T3 ES 2077345T3
Authority
ES
Spain
Prior art keywords
group
carbon atoms
mureidomycin
compound
tetrahydroisoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92202494T
Other languages
Spanish (es)
Inventor
Tatsuo Haneishi
Masatoshi Inukai
Keiko Shimizu
Fujio Isono
Yoshiharu Sakaida
Takeshi Kinoshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2077345T3 publication Critical patent/ES2077345T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

New antibiotics of the mureidomycin group have the formula <CHEM> wherein X represents the group <CHEM> and wherein R represents a hydrogen atom, an alkyl group having from 1 to 10 carbon atoms, an alkenyl group having from 2 to 7 carbon atoms, an alkynyl group having from 3 to 7 carbon atoms, an aryl group having from 6 to 10 carbon atoms, an aralkyl group having from 7 to 10 carbon atoms, or one of the said aryl or aralkyl groups substituted with at least one halogen atom and/or at least least one alkyl group having from 1 to 5 carbon atoms. The compound in which X represents 8-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin E and the compound in which X represents 6-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl is named mureidomycin F. This group of compounds and their pharmaceutically acceptable esters and salts are useful as antibiotics for the treatment of bacterial infections. Mureidomycins E and F can be obtained by fermentation of a suitable Streptomyces strain, in particular Streptomyces flavidovirens SANK 60486 (BIKOKEN JOHKI 1347; FERM BP-1347). ALternatively, all of the compounds can be obtained synthetically by reacting the previously known compound mureidomycin A with an aldehyde of the formula R - CHO.
ES92202494T 1987-11-20 1988-11-16 INTERMEDIARIES OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND USE. Expired - Lifetime ES2077345T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29335387 1987-11-20
JP29335287 1987-11-20

Publications (1)

Publication Number Publication Date
ES2077345T3 true ES2077345T3 (en) 1995-11-16

Family

ID=26559375

Family Applications (2)

Application Number Title Priority Date Filing Date
ES88310822T Expired - Lifetime ES2054829T3 (en) 1987-11-20 1988-11-16 ANTIBIOTICS OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND ITS USE.
ES92202494T Expired - Lifetime ES2077345T3 (en) 1987-11-20 1988-11-16 INTERMEDIARIES OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND USE.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES88310822T Expired - Lifetime ES2054829T3 (en) 1987-11-20 1988-11-16 ANTIBIOTICS OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND ITS USE.

Country Status (8)

Country Link
US (1) US5041423A (en)
EP (2) EP0517345B1 (en)
KR (2) KR0137779B1 (en)
AT (1) ATE125256T1 (en)
CA (1) CA1339595C (en)
DE (2) DE3880092T2 (en)
ES (2) ES2054829T3 (en)
HK (2) HK1003573A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487756A1 (en) * 1990-11-26 1992-06-03 Hoechst Aktiengesellschaft Antibiotics napsamycins A-D, process for their production and their use as pharmaceuticals
US6228842B1 (en) 1998-11-06 2001-05-08 Microcide Pharmaceuticals, Inc. Pacidamycins produced by Streptomyces coeruleorubidus
US6482921B1 (en) * 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
SI1430138T1 (en) * 2001-09-27 2006-04-30 Biocon Ltd Process for producing pravastatin sodium salt using streptomyces flavidovirens dsm 14455
KR102302414B1 (en) 2014-06-20 2021-09-16 주식회사 만도 Ground connectin structure between pcb and chassia for reducing impedance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3341571A1 (en) * 1983-11-17 1985-05-30 Bayer Ag, 5090 Leverkusen NEW ANTIBIOTICS, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
GB8421279D0 (en) * 1984-08-22 1984-09-26 Baldwin J E Antibiotics
IT1184164B (en) * 1985-03-19 1987-10-22 Eniricerche Spa TRIPTIDES WITH HYPOTHENSIVE ACTION AND PROCEDURE FOR THEIR SYNTHESIS
CA1339467C (en) * 1986-05-20 1997-09-16 Keiko Shimizu New antibiotics called "mureidomycins a, b, c and d", a process for their preparation and their therapeutic use

Also Published As

Publication number Publication date
DE3854205D1 (en) 1995-08-24
EP0317292A3 (en) 1990-07-25
HK1003573A1 (en) 1998-10-30
EP0517345A1 (en) 1992-12-09
ES2054829T3 (en) 1994-08-16
DE3854205T2 (en) 1996-04-04
ATE125256T1 (en) 1995-08-15
KR890008130A (en) 1989-07-08
DE3880092T2 (en) 1993-11-25
HK1005736A1 (en) 1999-01-22
KR0137675B1 (en) 1998-05-15
CA1339595C (en) 1997-12-23
EP0317292B1 (en) 1993-04-07
US5041423A (en) 1991-08-20
EP0517345B1 (en) 1995-07-19
KR0137779B1 (en) 1998-05-15
DE3880092D1 (en) 1993-05-13
EP0317292A2 (en) 1989-05-24

Similar Documents

Publication Publication Date Title
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
ATE89822T1 (en) HETEROCYCLIC DERIVATIVES SUBSTITUTED BY BENZHYDRYL N, THEIR PRODUCTION AND USE.
PT83843B (en) PROCESS FOR THE PREPARATION OF RAPAMICINE AVERAGES
AU8682191A (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
DK0615549T3 (en) Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds with a yeast reductase
FI911016A0 (en) Process for the preparation of pharmacologically active substituted diketones
ES2077345T3 (en) INTERMEDIARIES OF THE MUREIDOMICINA GROUP, ITS PREPARATION AND USE.
ES8506731A1 (en) Cephalosporin derivatives.
ZA894470B (en) Substituted 3-aminosydnone imines,a process for their preparation and their use
PT99250A (en) PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES
EP0367036A3 (en) Substituted 3-aminosydnonimines, process for their preparation and their use
ES2026548T3 (en) A PROCEDURE FOR PREPARING PENEMOS.
FI943596A (en) A process for the preparation of therapeutically useful macrolide compounds
NO167382C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 4-HYDROXY-4- (SUBSTITUTED ALKENYL) CYCLOHEXANCARBOXYL ACIDS.
CA1268121C (en) .alpha.-ALKYL POLYOLEFINIC CARBOXYLIC ACIDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF PSORIASIS AND ALLERGIC RESPONSES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517345

Country of ref document: ES